Prognosis of Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis: Insights From the API-CAT Randomized Trial

Dr. Isabelle MahéPrincipal Investigator

“Our study has shown for the first time that a 12-month extension of anticoagulant treatment with reduced-dose apixaban was comparable to full-dose apixaban in preventing a recurrence of VTE in patients with active cancer who have already received at least six months of VTE treatment. We can say that the lower-dose apixaban is both effective and safer than the full dose.”

“Exciting results presented by Prof Isabelle Mahé at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, with simultaneous publication in Circulation. Key findings from this pre-specified ancillary analysis of the API-CAT trial include: Recurrent VTE during extended apixaban therapy was uncommon, occurring in only 2.5% of 1,766 patients over 12 months.”

“The additional value of the results of the API-CAT trial lies with the investigators' decision to report patient-relevant bleeding outcomes. This reporting provides clinicians with much-needed information for them to engage in meaningful dialogue with patients in order to make anticoagulation decisions that are based on patients' values and preferences.”